Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, a synthetic biotechnology company, has announced a partnership with the World Wildlife Fund (WWF) to enhance ocean health and reduce the impact of fishing on shark populations. The collaboration aligns with Amyris' commitment to Environmental, Social, and Governance (ESG) goals, as highlighted in its 2021 ESG report. The partnership aims to promote sustainable fishing practices in Ecuador and Peru and will explore eco-friendly ingredients to mitigate ocean ecosystem impacts. This initiative underscores the need for corporate responsibility in biodiversity conservation.
Amyris, Inc. (Nasdaq: AMRS) announced the launch of two new consumer brands: Stripes™ for (peri)menopausal wellness and EcoFabulous™ for Gen-Z beauty. Stripes launched on October 18, 2022, while EcoFabulous debuted on October 20, 2022. Both brands will be available on Amazon in November and in retail stores soon. CEO John Melo reported strong consumer demand and expects a strong end to 2022, continuing to expand Amyris' portfolio, which includes popular brands like Biossance and Pipette.
Amyris, Inc. (Nasdaq: AMRS) announced the inclusion of its brands—Biossance, JVN Hair, and Rose Inc—in Sephora's UK launch on October 17, 2022. This move marks a significant expansion in the UK and is part of a global partnership with Sephora. With ongoing consumer demand for clean beauty products, Amyris has been recognized by Women's Wear Daily as a leading small cap beauty company. The company aims to bolster its offerings and retail presence in the UK and Europe while focusing on operational excellence and reduced costs.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology focused on sustainable consumer products, announced its participation in two investor conferences. The company will engage in fireside chats moderated by equity research analysts, providing updates on its operations. Key events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 AM ET (virtual) and the Piper Sandler Growth Frontiers Conference on September 13 at 3:30 PM CT (in-person, Nashville, TN). Live webcasts and replays of these presentations will be available on Amyris' Investor Relations website.
Amyris reported Q2 2022 core revenue of $65.2 million, a 54% increase year-over-year, fueled by record consumer revenue of $43 million, up 108%. Year-to-date, consumer revenue surged 113%. The company anticipates $50 million in EBITDA improvements for H2 2022 due to cost actions and price increases. A substantial $700 million in funding enhances liquidity for ongoing growth. However, cash operating expenses rose 73.7 million from Q2 2021, leading to a GAAP net loss of $110 million. The firm continues to expand its retail presence globally.
Amyris, a synthetic biotechnology leader, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 3:00 PM PT in Dana Point, CA. Chief Science Officer Sunil Chandran will represent the company during a fireside chat. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, which employs AI and robotics to scale innovation. The company provides sustainable ingredients used in over 20,000 products globally, reaching more than 300 million consumers.
Amyris, Inc. (Nasdaq: AMRS) announced its financial results for Q2 2022 will be shared on August 9, 2022, before market open. A conference call will follow at 6:00 a.m. PT to discuss these results and provide a business update by CEO John Melo and CFO Han Kieftenbeld. Amyris specializes in sustainable ingredients for Clean Health & Beauty and Flavors & Fragrances markets via its proprietary Lab-to-Market™ platform, reaching over 300 million consumers through 20,000 products.
Amyris, Inc. (Nasdaq: AMRS) announced the successful start of fermentation at its new precision fermentation plant in Barra Bonita, Brazil, marking a significant milestone. This facility, featuring five mini-factories, allows the company to produce all 13 market molecules concurrently, responding to rising demand for sustainable ingredients in beauty, health, and wellness. The plant's capacity is fully committed through 2023, enabling efficient supply to customers. COO Eduardo Alvarez praised the team's achievement in completing this state-of-the-art facility during the pandemic.
Amyris, a synthetic biotechnology company listed on Nasdaq as AMRS, will engage in a virtual fireside chat at the Oppenheimer 22nd Annual Consumer Conference on June 14, 2022, at 11:15 am ET. This event highlights Amyris's commitment to sustainable consumption through its Lab-to-Market™ technology platform, which utilizes advanced machine learning and robotics to accelerate innovation in the Clean Health & Beauty and Flavors & Fragrances markets. A webcast will be available on their Investor Relations page.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
